Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003036 · ClinicalTrials.gov registry record · NA
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Deepak K. Sarpal, M.D..
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06003036: Recruiting NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Deepak K. Sarpal, M.D..
NCT06003036 is a NA study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Deepak K. Sarpal, M.D.. The registered enrollment target is 30 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06003036, a NA study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Deepak K. Sarpal, M.D..
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.
Primary Outcome
Examine changes in left dorsolateral prefrontal cortex-basal forebrain functional connectivity following adjunctive accelerated intermittent theta burst stimulation (iTBS)
Conditions Studied
Interventions
- DEVICE transcranial magnetic stimulation
- DEVICE sham stimulation
Study Locations (1)
Pennsylvania
- UPMC Western Psychiatric Hospital/University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT06003036 shows while recruiting
NCT06003036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which transcranial magnetic stimulation is the first listed.
NCT06003036 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06003036 about?
NCT06003036 is a clinical study titled "Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine". In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic res...
What is the current status of trial NCT06003036?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-12-01. Estimated completion is 2026-07.
What conditions does trial NCT06003036 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT06003036?
The interventions under investigation include: transcranial magnetic stimulation (DEVICE), sham stimulation (DEVICE).
Who is sponsoring clinical trial NCT06003036?
This trial is sponsored by Deepak K. Sarpal, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003036 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06003036's enrollment target sits among peer trials
30 263rd of 315 higher than 49 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI